Division of Endocrinology, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.
Curr Opin Endocrinol Diabetes Obes. 2019 Feb;26(1):54-59. doi: 10.1097/MED.0000000000000452.
As the pace of genetic discovery accelerates, genetic sequencing is increasingly applied to rare disease such as DSD (differences or disorders of sex development,) which has led to an increase in the number of novel variant-containing candidate genes identified. In this review, we will discuss several candidate genes which have recently been proposed as causative of DSD, as well as novel work in understanding gene regulation in the mouse gonad that may have implications for the DSD phenotype in humans.
We performed a comprehensive search of PubMed through August 2018 to identify relevant peer-reviewed publications from 2017 to 2018 on DSD genetics.
Seminal work has identified a critical gonadal enhancer of Sox9 in a mouse model. This enhancer is located in a region which had previously been implicated in both XX and XY DSD, though the specific enhancer and its role in Sox9 gene expression had not been defined. Novel candidate genes in XY gonadal dysgenesis (SOX8, ESR2) and XX ovotesticular DSD (NR2F2) have been described.
随着基因发现速度的加快,基因测序越来越多地应用于罕见疾病,如 DSD(性别发育差异或障碍),这导致了鉴定出的含有新变异的候选基因数量的增加。在这篇综述中,我们将讨论最近被提出为 DSD 致病原因的几个候选基因,以及在理解小鼠性腺中的基因调控方面的新工作,这可能对人类 DSD 表型有影响。
我们通过 2018 年 8 月在 PubMed 上进行了全面搜索,以确定 2017 年至 2018 年关于 DSD 遗传学的相关同行评审出版物。
开创性的工作已经在小鼠模型中确定了 Sox9 的一个关键性腺增强子。这个增强子位于一个先前与 XX 和 XY DSD 都有关联的区域,尽管特定的增强子及其在 Sox9 基因表达中的作用尚未确定。在 XY 性腺发育不全(SOX8、ESR2)和 XX 卵睾性 DSD(NR2F2)中已经描述了新的候选基因。